Infervision vs Riverain Technologies (2026)
Both detect lung nodules on chest imaging as concurrent read tools, available alongside the radiologist's initial read rather than after it, so the split is breadth and regulatory reach against evidence you can inspect and a deployment that stays inside your institution. If you want the widest coverage and multi jurisdiction footprint, start with Infervision, which spans the widest scope in the imaging lane, but its published performance evidence is thin and it is China headquartered, which raises cross border data questions. If you want a focused lung nodule tool with an inspectable clearance record and imaging that stays on premise, start with Riverain, accepting an older and narrower product. Infervision is cleared across five regulatory regimes. Riverain was the first device cleared for concurrent reading.
- The widest scope in the imaging lane: lung CT, chest radiography, and coronary CTA detection plus surgical planning across thorax, liver, and urology and standardized tumor response assessment, far beyond Riverain's cardiothoracic focus.
- It is cleared across the US FDA, European CE, UK UKCA, Japan PMDA and China NMPA, with iterative US clearances including 4 mm nodule detection.
- Long running deployment at scale, more than 380 sites processing over 55,000 cases daily, including UN procured tuberculosis screening in low resource settings.
- An inspectable clearance record: performance broken out by nodule type, residual analysis across slice thickness, and a site configurable micro nodule threshold, where Infervision publishes no sensitivity, specificity, or reader study data at all.
- A distinct technical mechanism: deep learning vessel suppression that alters the image so both the algorithm and the human read better, cleared in 2016 as the first device supporting concurrent reading, with a multi reader study reporting a 29 percent reduction in missed actionable nodules.
- A deployment that keeps imaging inside the institution: it installs without new hardware and likely on premise, an advantage for buyers with data residency constraints, and it is US headquartered.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Infervision and Riverain Technologies are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Infervision | Riverain Technologies |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2015 | 2000 |
| Headquarters | Beijing, China | Miamisburg, Ohio, United States |
| Website | global.infervision.com | riveraintech.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Beijing based imaging AI company whose InferRead line detects findings on CT and radiographs (lung nodules on chest CT, chest abnormalities on radiographs, coronary stenosis on CTA, hemorrhage on head CT, chest fractures and pneumonia), alongside the InferOperate suite of 3D reconstructions for thoracic, liver and urologic surgical planning, InferCare for patient follow up and RECIST tumor assessment, and the InferScholar research and InferMatrix application platforms.
Source: AI Health Index, July 2026
Ohio based company whose ClearRead software applies AI to chest CT and chest radiographs. ClearRead CT produces a vessel suppressed series with nodule detection marks, cleared by the FDA in 2016 (K161201) as an aid to the radiologist for pulmonary nodules on chest CT in an asymptomatic population, and extends to coronary artery calcium scoring (K242188, 2024).
Source: AI Health Index, July 2026
Questions buyers ask
How do Infervision and Riverain Technologies work with the EHR?
For Infervision, the InferRead Lung CT.AI 510(k) summary (K240554) lists DICOM image input and reporting of results, with detection marks delivered as an overlay on the original CT. The product is reported in use at SimonMed, a US outpatient imaging provider, and in tuberculosis screening programs.
With Riverain Technologies, the 510(k) summaries describe delivery through the same DICOM network interface that supplies the CT series. The home page displays the names of health systems including the VA, Cleveland Clinic, Duke, Cedars-Sinai, Michigan Medicine and University Hospital Zurich, and reports more than 400 customer locations. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
How are Infervision and Riverain Technologies priced and sold?
In Infervision's case, the company is reported to offer several pricing options rather than a single model, and its tuberculosis screening deployments were procured through international agencies by public tender, where the price is disclosed to the purchaser rather than published. The products are sold directly and through public procurement, but what drives the cost is not stated.
For Riverain Technologies, one route to buy is public: ClearRead CT is listed as an application in the Sectra Amplifier Marketplace, the application store for Sectra's PACS, with its integration and regulatory details and no price or licensing terms. The company's home page gives no licensing basis, whether per site, per study or across a health network. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
How do Infervision and Riverain Technologies handle patient data?
With Infervision, the InferRead Lung CT.AI 510(k) summary (K240554) says the software can run in the healthcare facility or on a cloud platform, and that cybersecurity and vulnerability analyses found it conforms to the cybersecurity requirements, a general assurance about the product.
In Riverain Technologies' case, the K161201 summary describes a postprocessing application that generates a secondary series from the lung CT; where that processing runs, what is retained afterward, whether customer studies are used to train or improve the models, and whether any de identification is applied are not stated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
Which settings and specialties do Infervision and Riverain Technologies cover?
For Infervision, the lung nodule product is cleared for asymptomatic people aged 55 and over with nodules of 4 mm and larger on chest CT, and its 2025 summary tests its follow up functions on lung cancer screening scans; hemorrhage triage on head CT, surgical planning for thoracic, liver and urologic surgery, and RECIST tumor assessment carry their own US clearances.
With Riverain Technologies, the nodule detection clearance (K161201) covers chest CT in an asymptomatic population with both lungs in the field of view, supported by a multi reader study, so use on diagnostic chest CT in symptomatic patients falls outside the indication as summarized. Calcium scoring (K242188) and pneumothorax (K213566) are cleared; radiograph nodule detection has no US clearance stated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both detect lung nodules on chest imaging as concurrent read tools, available alongside the radiologist's initial interpretation rather than after it, which trades faster workflow for greater exposure to automation bias, the opposite of a second read design.
Infervision is the weaker on evidence despite its scale: no peer reviewed reader study, accuracy paper, or outcome data was located for any product in its line, and scale of use is not evidence of benefit, which matters most for its 4 mm nodule claim where false positive rates rise sharply. It is China headquartered and processes US and European imaging, so cross border data transfer terms are a live procurement question its materials do not address.
Riverain is an older generation of authorization with a narrow cardiothoracic scope, and its foundational clearance predates current standards such as Predetermined Change Control Plans. Neither publishes pricing or a security attestation.